Comparison of the effects of various vanadium salts on glucose homeostasis in streptozotocin-diabetic rats.
Oral administration of vanadium salts to severely diabetic rats lead to a spectacular decrease of plasma glucose levels in spite of the insulin deficiency of the animals. The insulin-like properties of vanadium have been attributed to the cationic form, vanadyl, into which the anionic form, vanadate, is reduced within cells. This has led to the suggestion that vanadyl is the form of choice for the treatment. In this study, rats made insulin-deficient and diabetic with streptozotocin were treated with three salts of vanadium: sodium orthovanadate, sodium metavanadate and vanadylsulfate. The salts were added to the drinking water, in concentrations that led to ingestion of the same amount of vanadium element by the three groups of rats (approximately 8 mg/kg per day). The initial, transient, loss of weight that affected the treated rats was slightly smaller in the vanadyl-treated group than in the vanadate-treated groups. However, during steady-state treatment, the three groups exhibited a similar food intake (lower than in controls) and growth rate (higher than in controls). The decreases in plasma glucose levels, in urinary volume and in glucosuria, and the improvement of the tolerance to an oral glucose load were similar regardless of the type of vanadium salt. Withdrawal of the treatment after 14 weeks was followed by a rapid increase in plasma glucose levels which, however, remained clearly lower than in controls for at least 4 weeks, whereas plasma insulin levels increased only transiently. A smaller glucosuria and a slightly better tolerance to oral glucose than in controls were still observed in the previously treated rats.(ABSTRACT TRUNCATED AT 250 WORDS)
Becker
D J
DJ
Unit of Endocrinology and Metabolism, University of Louvain, Brussels, Belgium.
Ongemba
L N
LN
Henquin
J C
JC
D000704:Analysis of Variance; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000188:drug therapy; D004195:Disease Models, Animal; D006029:Glycosuria; D006706:Homeostasis / Q000187:drug effects; D007328:Insulin / Q000172:deficiency; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin / Q000633:toxicity; D014638:Vanadates / Q000494:pharmacology* / Q000627:therapeutic use; D017968:Vanadium Compounds / Q000494:pharmacology* / Q000627:therapeutic use
D001786:Blood Glucose; D007328:Insulin; D017968:Vanadium Compounds; D014638:Vanadates; D013311:Streptozocin; C034028:vanadyl sulfate